BioNTech to Acquire US FDA Priority Review Voucher

BioNTech has agreed to acquire a US FDA Priority Review Voucher from Scholar Rock for $205 million. The voucher allows BioNTech to expedite FDA review for a single drug application, potentially accelerating market entry in the United States.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 10 Nov 2026 and 12 Nov 2026.